Skip to main content
NewslettersWatchlist

Teva Pharmaceutical Industries ADR(TEVA-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Teva Pharmaceutical Industries ADR

124 DVORA HANEVI'a STREET
TEL AVIV L3 6944020 ISR
P: 972-3914-8213
http://www.tevapharm.com

Sectors & Indices

Sector
Industry
Employees

Profile

Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs, as well as active pharmaceutical ingredients in North America, Europe, Latin America, India, and Israel. Teva's generic product portfolio includes tablets, capsules, liquids, ointments, creams, liquids, injectables, and inhalants. The company's branded products include Copaxone, Austedo, respiratory products like ProAir and Qvar and Ajovy. Teva operates through three segments, North America, Europe and International Markets, each of which includes generics, specialty and over-the-counter products. Teva acquired Allergan's generics business Actavis Generics. The company also acquired Allergan's Anda Inc. Teva acquired Auspex Pharmaceuticals and Barr. Teva has strengthened its position in Europe through its acquisition of Germany's second largest generics producer, ratiopharm.

Key Executives

NameTitle
Richard FrancisCEO/Director/President
Eli KalifCFO/Executive VP
Amir WeissChief Accounting Officer/Senior VP

More from The Globe

The close: Stocks higher as investors focus on Fed moves
Traders work on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., April 26.
The close: Major North American indexes rise as megacap tech stocks rally
A trader works on the floor at the New York Stock Exchange (NYSE) on April 25.
Why this money manager is venturing back into emerging markets and adding more U.S. tech
Illustration of Andrew Pyle for The Mover. Nov. 5, 2022. Illustration by Joel Kimmel
How a Canadian pirate-clad pastor helped ignite Trump Media’s market frenzy
Former President Donald Trump sits in Manhattan Criminal Court in New York, Thursday, April 25.
Activist investor targets Dye & Durham’s ‘underperformance and strategic missteps’ in letter to shareholders
Dye & Durham Ltd. says it has launched a strategic review of its non-core assets in an effort to reduce its debt. The logo for Dye & Durham Ltd. is shown in this undated handout photo. THE CANADIAN PRESS/HO
The close: U.S. stocks fall as GDP report spreads rate-cut gloom; Alphabet surges 15% in post market
Traders work on the floor of the New York Stock Exchange shortly after the opening bell, Wednesday, April 24.
Fiera Capital’s largest shareholder looks to sell stake in company
Jean-Guy Desjardins, global CEO and founder of Fire Capital posses for a portrait at Fiera Capital, in Montreal on Monday, January 8, 2024. Evan Buhler/The Globe and Mail�
The close: S&P 500 higher as markets weigh rising bond yields and upbeat U.S. earnings; TSX lower as rails slide
The Art Deco facade of the original Toronto Stock Exchange building is seen on Bay Street in Toronto in January of 2019.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Financial data provided by Zacks Investment Research.